Advertisement

Tumor Biology

, Volume 36, Issue 8, pp 5753–5755 | Cite as

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer

  • Paula González-Alonso
  • Ion Cristóbal
  • Rebeca Manso
  • Juan Madoz-Gúrpide
  • Jesús García-Foncillas
  • Federico Rojo
Research Commentary

Abstract

Protein phosphatase 2A (PP2A) is a well-known tumor suppressor frequently inhibited in human cancer. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. Moreover, recent findings highlight that functional inactivation of PP2A could represent a key event in the acquisition of castration-resistant phenotype and a novel molecular target with high impact at both clinical and therapeutic levels in prostate cancer.

Keywords

PP2A FTY720 Cabazitaxel Castration-resistant prostate cancer 

Notes

Financial support

This study is supported by the Biobank of “Fundación Jiménez Díaz” (FJD Biobank) (RD12/0036/0021), and PI12/01552 and PI13/02609 grants from “Instituto de Salud Carlos III FEDER” and S2010/BMD2344. R. Manso and P. González-Alonso are supported by “Fundación Conchita Rábago de Jiménez Díaz”.

Conflicts of interest

None

References

  1. 1.
    Huang J, Jia J, Tong Q, Liu J, Qiu J, Sun R, et al. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy. Tumour Biol. 2015;36:1589–94.CrossRefPubMedGoogle Scholar
  2. 2.
    Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015; In press.Google Scholar
  3. 3.
    Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, Chen CS. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis. 2009;30:1125–31.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, Singh AP. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther. 2011;10:720–31.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21:795–807.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Khanna A, Rane JK, Kivinummi KK, Urbanucci A, Helenius MA, Tolonen TT, et al. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. Oncotarget. 2015; In press.Google Scholar
  7. 7.
    Guo Z, Liu D, Su Z. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway. Tumour Biol. 2015;36:3583–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Pusey M, Nickels JT Jr, et al. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells. Tumour Biol 2015; In press.Google Scholar
  9. 9.
    Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Nickels JT Jr, Rice LM. Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin. Tumour Biol 2015; In press.Google Scholar
  10. 10.
    Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, et al. Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs. 2015;13:3276–86.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bhardwaj A, Singh S, Srivastava SK, Arora S, Hyde SJ, Andrews J, et al. Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br J Cancer. 2014;110:2000–10.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res. 2013;11:568–78.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pandey P, Seshacharyulu P, Das S, Rachagani S, Ponnusamy MP, Yan Y, et al. Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br J Cancer. 2013;108:2590–600.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther. 2013;14:962–72.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Paula González-Alonso
    • 1
  • Ion Cristóbal
    • 2
  • Rebeca Manso
    • 1
  • Juan Madoz-Gúrpide
    • 1
  • Jesús García-Foncillas
    • 2
  • Federico Rojo
    • 1
  1. 1.Pathology DepartmentIIS “Fundación Jiménez Diaz”MadridSpain
  2. 2.Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAMUniversity Hospital “Fundacion Jimenez Diaz”MadridSpain

Personalised recommendations